AMR Logo.png
Global Human Growth Hormone Market to reach $9.21 billion by 2030: Allied Market Research
October 11, 2021 04:12 ET | Allied Market Research
Portland, OR, Oct. 11, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Human Growth Hormone Market generated $3.86 billion in 2020, and is projected...
Logo 1.png
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 13, 2021 08:05 ET | Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
gmi logo.jpg
Growth Hormone Market revenue to cross USD 5.3 Bn by 2027: Global Market Insights Inc.
April 29, 2021 07:00 ET | Global Market Insights, Inc
Selbyville, Delaware, April 29, 2021 (GLOBE NEWSWIRE) -- According to latest report “Growth Hormone Market by Product (Powder, Solvent), Application (Growth Hormone Deficiency, Idiopathic Short...
Logo 1.png
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 22, 2021 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
September 08, 2020 08:05 ET | Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
March 04, 2019 06:30 ET | Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
January 07, 2019 09:00 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
September 17, 2018 16:10 ET | Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...